GTP Bioways
GTP Bioways is a customer-centric and science-driven CDMO specializing in process development and manufacturing of biologics, antibody conjugates, nanodrugs, and complex bioconjugates. With facilities in France, they support biopharma companies from preclinical to commercial production, offering tailored solutions and expertise across all stages of biotherapeutics development. Their services include R&D, process development, analytical development, GMP manufacturing, fill & finish, and project management, with a focus on innovation, quality, and collaboration. They also provide specialized analytical services such as host cell protein detection and custom immunoassay development, and advanced purification techniques for ADCs.
Industries
Nr. of Employees
medium (51-250)
GTP Bioways
18, rue Jean Perrin, 31100 Toulouse, France
Products
GMP Manufacturing
Manufactures preclinical, clinical, and small commercial batches of innovative therapies in GMP facilities.
Process Development
Develops manufacturing processes for proteins, antibodies, bioconjugates, and nanodrugs.
Analytical Development
Provides method development for mammalian, microbial, and bioconjugate manufacturing.
Fill & Finish
Offers aseptic filling for liquid drug product manufacturing.
R&D Services
Provides custom production services with various expression systems for recombinant proteins.
Monoclonal Antibodies
Produces monoclonal antibodies for various applications.
GMP Manufacturing
Manufactures preclinical, clinical, and small commercial batches of innovative therapies in GMP facilities.
Process Development
Develops manufacturing processes for proteins, antibodies, bioconjugates, and nanodrugs.
Analytical Development
Provides method development for mammalian, microbial, and bioconjugate manufacturing.
Fill & Finish
Offers aseptic filling for liquid drug product manufacturing.
R&D Services
Provides custom production services with various expression systems for recombinant proteins.
Monoclonal Antibodies
Produces monoclonal antibodies for various applications.
Services
End-to-end recombinant protein and antibody production across multiple expression systems for R&D and preclinical supply.
Upstream and downstream process development, purification optimisation, conjugation process support and scale‑up readiness for proteins, ADCs and nano‑formulations.
EU GMP-compliant manufacture of clinical and small commercial batches for biologics, ADCs and nanodrugs, with integrated QA/QC and release testing.
Isolator‑based aseptic filling services for liquid drug products with in‑house formulation, stability and QC support, suitable for biotech products, nanocarriers and highly potent molecules.
Analytical method development, validation, stability testing, custom ELISA and HCP assay development, and advanced characterisation to support process development and GMP release.
Documentation, process transfer runs, containment planning and regulatory support to enable transfer from development to GMP manufacture and clinical supply.
End-to-end recombinant protein and antibody production across multiple expression systems for R&D and preclinical supply.
Upstream and downstream process development, purification optimisation, conjugation process support and scale‑up readiness for proteins, ADCs and nano‑formulations.
EU GMP-compliant manufacture of clinical and small commercial batches for biologics, ADCs and nanodrugs, with integrated QA/QC and release testing.
Isolator‑based aseptic filling services for liquid drug products with in‑house formulation, stability and QC support, suitable for biotech products, nanocarriers and highly potent molecules.
Analytical method development, validation, stability testing, custom ELISA and HCP assay development, and advanced characterisation to support process development and GMP release.
Documentation, process transfer runs, containment planning and regulatory support to enable transfer from development to GMP manufacture and clinical supply.
Expertise Areas
- End-to-end CMC and CDMO services for biologics
- Process development for proteins, antibodies and antibody–drug conjugates (ADCs)
- GMP manufacturing and aseptic fill & finish for biologics and highly potent products
- Formulation development and stability assessment for biologics and nanoformulations
Key Technologies
- Custom ELISA and immunoassay platforms
- 2D electrophoresis (2D-DIGE/2D-DIBE)
- Mass spectrometry (ESI-MS, MALDI-TOF, high-resolution MS) for protein, glycan and impurity analysis
- Chromatography (affinity, ion-exchange, hydrophobic interaction, GC)
News & Updates
Discussion on the challenges of ADC development and manufacturing, including target selection, linker, payload, and clinical applications.
Case study on developing a viral inactivation process for a complex recombinant protein for COVID-19 vaccine.
Optimizing a purification process for a recombinant protein struggling with host cell protein contamination.
Guidance on selecting the right CDMO for biologics development, emphasizing project understanding, tailored approach, and collaboration.
Discussion on the challenges of ADC development and manufacturing, including target selection, linker, payload, and clinical applications.
Case study on developing a viral inactivation process for a complex recombinant protein for COVID-19 vaccine.
Optimizing a purification process for a recombinant protein struggling with host cell protein contamination.
Guidance on selecting the right CDMO for biologics development, emphasizing project understanding, tailored approach, and collaboration.